A practical reference on REV-ERB: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
where χi denotes the mole fraction of component i. For greater accuracy, the critical point can be calculated using equations of state, such as the Peng–Robinson, or group-contribution methods. Other properties, such as density, can also be calculated using equations of state.
A macrophagic myofasciitis (MMF) lesion a histopathological finding involving inflammatory microphage formations with aluminium-containing crystal inclusions and associated microscopic muscle necrosis in biopsy samples of the injection site. A MMF "syndrome" refers to a muscle pain or weakness that, when biopsied, often results in the observation of a MMF lesion. It is dubious whether the systemic "syndrome" represents a biological process connected to the local lesion, or even whether it is a specific condition. Most cases are reported in France, where there are more than 600 diagnoses among an immunized population of more than 64 million. The World Health Organization has concluded that
Taruc Hukbalahap Monument at Garden of Peace Memorial Park in Santa Monica, San Luis, Pampanga, was unveiled to honor about 400 guerrilla fighters (including Luis Taruc, the late Antonio Sumang and 96-year-old Praxedes Clarin, in the statue, one of the nine surviving Huks) including Olimpia Ingal, Narciso Garcia, Josefa Tolentino, and Clemente Miranda, all 94, Dominga Sanchez, Anastacia Sali, and Natalia Lacanlale, all 98 and Francisca Salas, 99).
=== Replacement by cysteine in mammals === Most mammal selenoproteins have a small amount (about 10%) of the selenocystine replaced by cystine, increasing to 50% on selenium-deficient diets. This is achieved by SLA/LP accepting thiophosphate instead of selenophosphate, thereby converting the phosphoseryl into a regular cystyl.
it is our view that Canada's proposal to legalize cannabis shares the objectives agreed to by member states in multilateral declarations", citing protection of vulnerable citizens, evidence-based policy, and public health, safety and welfare as "the heart of a balanced approach to treaty implementation." The CND and INCB stated, "this decision contravenes the provisions of the drug control conventions, and undermines the international legal drug control framework and respect for the rules-based international order." In Mexico, the Supreme Court in 2018 overturned as unconstitutional the prohibition of recreational cannabis use and ordered the government to enact corresponding legislation. In 2021, the Mexican Congress had still failed to change the laws, and the Court legalized personal use of cannabis. However, without updated legislation, the situation remains murky. Individuals have to apply for a permit and the federal criminal code with respect to recreational use has not been changed. The INCB, in its 2022 "Analysis of the world situation", reported, "In Mexico, legislative and policy changes concerning cannabis use for non-medical purposes continue to be in flux." In 2021, Malta legalized cannabis, the first EU country to do so. It adopted a law echoing article 2(9) of the Single Convention (exemption for the use of drugs for industrial purposes), leading some scholars to consider it the first national legalization to achieve compliance with the drug control treaties.
Sources: en.wikipedia.org
== Classification == CDPSs can be divided into two distinct subfamilies named NYH and XYP, distinguished depending on the conserved residues within their respective active sites, which let experts predict their aminoacyl-tRNA substrates. Both subfamilies mainly differ in the first half of their Rossmann fold, this two structures correspond to two different structural solutions to facilitate the reactivity of the catalytic serine residue. Some NYH’s crystal structures have been identified. These CDPSs’ structure contain a Rossmann fold domain. NYH form a larger group than XYP, therefore there is more information about them than about the XYP subfamily.
==== 118A>G variant ==== While over 100 variants have been identified for the opioid mu-receptor, the most studied mu-receptor variant is the non-synonymous 118A>G variant, which results in functional changes to the receptor, including lower binding site availability, reduced mRNA levels, altered signal transduction, and increased affinity for beta-endorphin. In theory, all these functional changes would reduce the impact of exogenous opioids, requiring a higher dose to achieve the same therapeutic effect. This points to a potential for greater addictive capacity in individuals who require higher dosages to achieve pain control. Evidence linking the 118A>G variant to opioid dependence is mixed, with associations shown in some study groups but negative results in other groups. One explanation for the mixed results is the possibility of other variants that are in linkage disequilibrium with the 118A>G variant and thus contribute to different haplotype patterns more specifically associated with opioid dependence.
== Adverse effects == The most common side effects of pivekimab sunirine include swelling (edema), tiredness (fatigue), muscle and joint pain (musculoskeletal pain), bleeding (hemorrhage), infusion-related reactions, nausea, diarrhea, changes in kidney function tests (increased creatinine), low albumin levels, and changes in liver function tests (transaminases increased). The US prescribing information includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease, and warnings and precautions for infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity. Pivekimab sunirine may cause a severe form of liver damage (hepatotoxicity) called veno-occlusive disease (blockage of small blood vessels that makes it hard for blood to leave the liver, leading to backup and swelling), including severe or fatal hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome). Pivekimab sunirine may cause a serious side effect called infusion-related reaction, which may be life-threatening or lead to death if not treated. Pivekimab sunirine contains sulfite and may cause severe, life-threatening allergic reactions in some people. Pivekimab sunirine may cause severe fluid retention and harm to an unborn baby.
== Preparation and use == Fruits can be dried whole (e.g., grapes, berries, apricot, plum), in halves, or as slices (e.g., mango, papaya, kiwi). Alternatively, they can be chopped after drying (e.g., dates), made into pastes, or concentrated juices. The residual moisture content can vary from small (3–8%) to substantial (16–18%), depending on the type of fruit. Fruits can also be spread out, dried and cut into strips in its puree form without the addition of sugar or fats with at least 50% moisture content as fruit leather, (see patent listed under the references section) or as a powder by spray or drum drying. They can be freeze dried. Fresh fruit is frozen and placed in a drying chamber under a vacuum. Heat is applied, and water evaporates from the fruit while it is still frozen. The fruit becomes very light and crispy and retains much of its original flavor. Dried fruit is widely used by the confectionery, baking, and sweets industries. Food manufacturing plants use dried fruits in various sauces, soups, marinades, garnishes, puddings, and food for infants and children. As ingredients in prepared food, dried fruit juices, purées, and pastes impart sensory and functional characteristics to recipes:
Certain countries and trade blocs establish programmes for high-frequency and/or low-risk travellers to expedite border controls, subjecting them to lighter or automated checks or priority border-control facilities. In some countries, citizens or residents have access to automated facilities not available to foreigners. The following expedited border control programmes are currently in effect:
Sources: en.wikipedia.org
After several years of researching disgust, Jonathan Haidt, and others, studied its opposite; the term "elevation" was coined. Elevation is a pleasant moral emotion, triggered by witnessing virtuous acts of remarkable moral goodness and resulting in a desire to act morally and do "good". As an emotion it has a biological basis, and is sometimes characterized by a feeling of expansion in the chest or a tingling feeling on the skin.
=== Troll Center case === In January 2016, the El Diario de Hoy and La Prensa Gráfica newspapers reported that the Búnker digital-programming company had created mirror sites of the newspapers in June 2015 and posted false information in an attempt to damage their reputations; the newspapers described the incident as a cyberattack. In a subsequent investigation by the office of the attorney general (FGR), Bukele allegedly instructed a Twitter user to create the mirror sites. Bukele denied involvement in the creation of the mirror sites. The incident became known as the "Troll Center" case. Five people were charged in relation to the case, but the charges were dropped in December 2017. On 4 July 2017, Bukele sued La Prensa Gráfica for $6 million, alleging that the newspaper had defamed and slandered him in its reporting of the cyberattacks by "falsely" ("falsamente") connecting him to the Troll Center case and "damag[ing] [Bukele's] image" ("dañó la imagen del señor alcalde"). Later that month, a court dismissed Bukele's lawsuit and three other courts rejected his appeals. In December 2018, the FGR stated that it had reviewed information supposedly linking Bukele's cell phone to the cyberattacks.
==== Accusations of Hezbollah using human shields ==== There have been claims that Hezbollah has intentionally drawn fire to Christian areas in southern Lebanon. Christians in the town of Rmaich clashed with Hezbollah due to the organization's attempts to establish military infrastructure in the town. The residents also wrote a complaint letter. On 26 March 2024, civilians in Rmaich confronted militants and rang their church bells after Hezbollah attempted to place rocket launchers in the town. Hezbollah denied trying to fire rockets from Rmaich. On 30 November 2024, the IDF said that it killed armed Hezbollah operatives near a church in southern Lebanon. A video appearing to be in the town of Khiyam, showed a tunnel shaft used to store weapons at the church. The Lebanese Kataeb Party criticized Hezbollah for allegedly storing weapons between houses stating that "Hiding weapons between houses does not support Gaza" after an IDF strike on Hezbollah infrastructure in Adloun. Rockets were still exploding about an hour after the strike was reported and the blasts lightly injured three citizens as shrapnel from the explosions flew to surrounding villages. These ammunition depots "open the door to Israeli attacks and turn the Lebanese into human shields", the Kataeb party said. According to IDF's Arabic spokesman, Avichay Adraee, Hezbollah-run yellow ambulances have been used to transport fighters and weapons.
In geochemistry, geophysics and nuclear physics, primordial nuclides, or primordial isotopes, are nuclides found on Earth that have existed in their current form since before Earth was formed. Primordial nuclides were present in the interstellar medium from which the Solar System was formed, and were formed in the Big Bang, by nucleosynthesis in stars and supernovae followed by mass ejection, by cosmic ray spallation, or from other processes throughout the history of the universe. They are the stable nuclides plus the fraction of the long-lived radionuclides surviving from the primordial solar nebula through planet accretion until the present; 286 such nuclides are known.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.